Download PDFPDF
When off-label is a good practice: the example of paracetamol and salbutamol
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    A first step towards safer drugs in children: Angelini updates paracetamol SPC
    • Jenny Bua, MD, MSc
    • Other Contributors:
      • Ines L'Erario, Egidio Barbi, Federico Marchetti

    Sir, with regard to the article we recently published on “wrong-label” drugs in Italy (1), we are very pleased to communicate that very recently Angelini, the pharmaceutical company producing paracetamol and appearing in our article because of its “wrong-label”, finally updated its Summary Product Characteristics (SPC). The updated SPC now reports appropriate dosages per kilogram, per narrower age ranges, together with the...

    Show More
    Conflict of Interest:
    None declared.